Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs

American Journal of Veterinary Research

Volumn 69, Issue 9, 2008, Pages 1203-1209

  Punke, John P ^a,b   Speas, Abbie L ^a   Reynolds, Lisa R ^a   Budsberg, Steven C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; FIROCOXIB; LEUKOTRIENE B4; MELOXICAM; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREVICOX; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTANOID; SALAZOSULFAPYRIDINE; TEPOXALIN; THROMBOXANE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; COLITIS; CONTROLLED STUDY; DIARRHEA; DOG DISEASE; DRUG DOSE INCREASE; DUODENUM BIOPSY; FEMALE; LEUKOTRIENE BLOOD LEVEL; MALE; NONHUMAN; OSTEOARTHRITIS; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS INHIBITION; STOMACH BIOPSY; SYNOVIAL FLUID LEVEL; VOMITING;

4-BUTYROLACTONE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOG DISEASES; DOGS; DUODENUM; FEMALE; INTESTINAL MUCOSA; LEUKOTRIENES; MALE; OSTEOARTHRITIS; PROSTAGLANDINS; PYRAZOLES; SULFONES; SYNOVIAL FLUID; THIAZINES; THIAZOLES;

ANIMALIA; CANIS FAMILIARIS;

EID: 52649180668     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.9.1203     Document Type: Article

References (18)

1. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006;82:186-191.
2. Bergh MS, Budsberg SC. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005;19:633-643.
3. Sigthorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity and pathogenesis of NSAID-enteropathy in mice. Gastroenterology 2002;122:1913-1923.
4. Whittle BJR. Mechanism underlying intestinal injury induced by antiinflammatory COX inhibitors. Eur J Pharmacol 2004;500:427-439.
5. Kawai S. Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res 1998;47(suppl 2): S102-S106.
6. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996;25:279-298.
7. Jones RD, Baynes RE, Nimitz CT. Nonsteroidal anti-inflammatory drug toxicosis in dogs and cats: 240 cases (1989-1990). J Am Vet Med Assoc 1992;201:475-477.
8. Lascelles BD, Blikslager AT, Fox SM, et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 2005;227:1112-1117.
9. Jones CJ, Streppa HK, Harmon BG, et al. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 2002;63:1527-1531.
10. Agnello KA, Reynolds LR, Budsberg SC. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:966-972.
11. Sessions JK, Reynolds LR, Budsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:812-817.
12. Argentieri DC, Ritchie DM, Ferro MP, et al. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994;271:1399-1408.
13. Takeuchi K, Ukawa H, Kato S, et al. Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E-receptor subtype EP3. Gastroenterology 1999;117:1128-1135.
14. Akiba Y, Guth PH, Engel E, et al. Dynamic regulation of mucus gel thickness in rat duodenum. Am J Physiol Gastrointest Liver Physiol 2000;279:G437-G447.
15. Narita T, Okabe N, Hane M, et al. Nonsteroidal antiinflammatory drugs induce hypermotilinemia and disturbance of inter-digestive migrating contractions in instrumented dogs. J Vet Pharmacol Ther 2006;29:569-577.
16. Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002;51:135-143.
17. McCann ME, Andersen DR, Zhang D, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 2004;65:503-512.
18. Streppa HK, Jones CJ, Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res 2002;63:91-94.